| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
81,430,000 |
| Market
Cap: |
1.14(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.89 - $14.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mind Medicine Mindmed is a clinical stage biopharmaceutical company developing products to treat brain health disorders, with a focus on psychiatry, addiction, pain and neurology. Co.'s drug candidates include: MM-120, which is a proprietary, pharmaceutically optimized form of lysergide, and is being developed for the treatment of generalized anxiety disorder; MM-110, which is its proprietary form of 18-methoxycoronaridine, a congener of ibogaine, that is being developed for the treatment of opioid withdrawal; and MM-402, which is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, that is developed for the treatment of main symptoms of autism spectrum disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
7,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$45,070 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
42,667 |
87,446 |
133,276 |
222,338 |
| Total Sell Value |
$560,939 |
$998,430 |
$1,310,074 |
$1,971,151 |
| Total People Sold |
3 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
6 |
9 |
19 |
| End Date |
2025-10-09 |
2025-07-08 |
2025-01-07 |
2024-01-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Karlin Dan |
Chief Medical Officer |
• – – |
2025-12-26 |
4 |
AS |
$13.15 |
$73,623 |
D/D |
(5,600) |
425,025 |
|
4% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2025-12-26 |
4 |
AS |
$13.15 |
$339,072 |
D/D |
(25,791) |
778,477 |
|
4% |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2025-12-26 |
4 |
AS |
$13.15 |
$148,244 |
D/D |
(11,276) |
282,576 |
|
4% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2025-09-25 |
4 |
AS |
$9.77 |
$75,268 |
D/D |
(7,704) |
430,625 |
|
40% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2025-09-25 |
4 |
AS |
$9.77 |
$252,037 |
D/D |
(25,797) |
804,268 |
|
40% |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2025-09-25 |
4 |
AS |
$9.77 |
$110,186 |
D/D |
(11,278) |
293,852 |
|
40% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2025-06-25 |
4 |
AS |
$6.80 |
$53,366 |
D/D |
(7,848) |
438,329 |
|
108% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2025-06-25 |
4 |
AS |
$6.80 |
$180,139 |
D/D |
(26,491) |
830,065 |
|
108% |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2025-06-25 |
4 |
AS |
$6.80 |
$78,139 |
D/D |
(11,491) |
305,130 |
|
108% |
|
| Liao Carrie |
Chief Accounting Officer |
• – – |
2025-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
142,270 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2025-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
350,000 |
877,764 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2025-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
453,013 |
|
- |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2025-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
323,197 |
|
- |
|
| Liao Carrie |
Chief Accounting Officer |
• – – |
2024-12-26 |
4 |
AS |
$7.43 |
$16,888 |
D/D |
(2,273) |
97,270 |
|
-15% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2024-12-26 |
4 |
AS |
$7.43 |
$49,357 |
D/D |
(6,643) |
338,013 |
|
-15% |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2024-12-26 |
4 |
AS |
$7.43 |
$33,576 |
D/D |
(4,519) |
173,197 |
|
-15% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2024-12-26 |
4 |
AS |
$7.43 |
$141,958 |
D/D |
(19,106) |
526,666 |
|
-15% |
|
| Gryska David W |
|
– • – |
2024-12-05 |
4 |
B |
$7.17 |
$17,925 |
D/D |
2,500 |
19,851 |
0.01 |
-19% |
|
| Liao Carrie |
Chief Accounting Officer |
• – – |
2024-09-25 |
4 |
AS |
$5.98 |
$14,065 |
D/D |
(2,352) |
99,543 |
|
57% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2024-09-25 |
4 |
AS |
$5.98 |
$118,231 |
D/D |
(19,771) |
545,772 |
|
57% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2024-09-25 |
4 |
AS |
$5.98 |
$41,089 |
D/D |
(6,871) |
344,656 |
|
57% |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2024-09-25 |
4 |
AS |
$5.98 |
$26,491 |
D/D |
(4,430) |
177,716 |
|
57% |
|
| Gryska David W |
|
– • – |
2024-08-23 |
4 |
B |
$5.98 |
$20,930 |
D/D |
3,500 |
17,351 |
0.01 |
25% |
|
| Wernli Miri Halperin |
Executive President |
• – – |
2024-08-21 |
4 |
D |
$6.17 |
$201,111 |
D/D |
(32,595) |
202,405 |
|
- |
|
| Wernli Miri Halperin |
Executive President |
• – – |
2024-08-21 |
4 |
OE |
$3.70 |
$185,000 |
D/D |
50,000 |
235,000 |
|
- |
|
106 Records found
|
|
Page 1 of 5 |
|
|
0.52 (3.85%) 
